Cardiovascular gene delivery: The good road is awaiting

被引：44

作者：

Brewster, L. P.

Brey, E. M.

Greisler, H. P.

机构：

[1] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA

[2] Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA

[3] IIT, Dept Biomed Engn, Chicago, IL 60616 USA

[4] Edward J HInes Jr VA Hosp, Res & Surg Serv, Hines, IL 60141 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2006年 / 58卷 / 04期

关键词：

thrombosis; myointimal hyperplasia (IH); gene delivery; endothelialization; endothelial cell (EC); vascular smooth muscle cell (SMC); extracellular matrix (ECM);

D O I：

10.1016/j.addr.2006.03.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials. (c) 2006 Elsevier B.V. All rights reserved.

引用

页码：604 / 629

页数：26

共 245 条

[101] Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial [J].